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Although ionising radiation has proven beneficial in the diagnosis and therapy of a number of diseases, 
one should keep in mind that irradiating healthy tissue may increase the risk of cancer. In order to justify 
an exposure to radiation, both the benefits and the risks must be evaluated and compared. The deleterious 
effects of medium and high doses are well known, but it is much less clear what effects arise from low 
doses (below 0.1 Gy), which is why such risk estimates are extremely important. This review presents the 
current state, important assumptions and steps being made in deriving cancer risk estimates for low dose 
exposures.
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Its great benefits aside, any use of ionising 
radiation in the diagnosis and treatment of disease is 
also a potential threat for the occurrence of unwanted, 
harmful effects. Ionising radiation can damage DNA, 
either directly due to an ejected electron or indirectly 
through the production of free radicals. Among the 
many types of DNA damage, double strand breaks 
(DSBs) are considered to be the most dangerous, as 
they can lead to cell death or carcinogenesis and 
heritable effects if their reparation fails (1). 
It is very important to know what kind of health 
risks arise from specific radiation doses. Sufficiently 
high doses of radiation (above 0.5 Gy) will kill a 
sufficient number of cells to cause tissue reactions 
(“deterministic effects”) (2). Deterministic effects are 
characterised by threshold doses below which effects 
do not occur and the severity of effects increases as 
the dose increases. Radiosurgery and radiotherapy use 
very high doses for killing off (or disabling) cancer 
cells. Non-lethal cell damage can cause cancer and 
heritable effects (“stochastic effects”) and the 
probability (but not severity) of stochastic effects 
depends on the dose (2). 
During diagnostic radiology all organs, and during 
radiotherapy and radiosurgery out-of-field organs, are 
exposed to low doses (below 0.1 Gy). That is why 
knowledge on cancer risk estimates for low doses is 
very important. Lately, this topic has attracted 
increased interest due to three main reasons. First, 
developments in photon therapy techniques such as 
Intensity Modulated Radiotherapy (IMRT) and 
tomotherapy have yielded a more conformal target 
dose distribution but, compared to previous 
conventional radiotherapy techniques, whole body 
exposure to low doses from scattered and leakage 
radiation has increased. The increasing use of these 
new techniques has raised interest regarding second 
cancer risk for patients undergoing radiotherapy. 
Second, the prognosis for many cancers, including 
some that largely rely on radiotherapy (e.g., prostate, 
breast, etc.), is steadily improving; an increasing 
number of patients are surviving periods comparable 
to or larger than the latent period for the incidence of 
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a cancer induced by radiation. Third, the use of 
Computed Tomography (CT) constantly and 
significantly increases. CT has established itself as an 
essential tool, not only for diagnosis but also for the 
follow-up of diseases, as an aid in intervention and 
for radiotherapy imaging. It is associated with low 
doses (organ doses within the scanned volume are 
typically a few tens of mGy), but doses considerably 
larger in comparison to corresponding conventional 
radiographs (3). Many medical procedures require 
more than one CT scan, which increases the cumulative 
patient dose. Finally, it should be emphasized that 
children are of particular interest because cancer risks 
generally increase strongly as age lowers and children 
are expected to survive for periods much longer than 
the latent period of irradiation-induced cancer 
incidence.
This paper describes the current state and important 
assumptions and steps being made in deriving cancer 
risk estimates after exposures to low doses of X and 
gamma rays. The upper limit for the low dose region 
is not strictly defined, but this article assumes them to 
be below 0.1 Gy (4). 
Cancer risk estimate for low doses
The statistical models describing the dose-cancer 
risk relationship used here have been derived from 
data gathered in epidemiological studies taking into 
account experimental results from radiobiology (2, 
13-15). Epidemiology is used to quantify risk from 
past exposures by following and comparing irradiated 
and non-irradiated populations. 
The most important epidemiological study for 
cancer risk modelling is the study on Japanese atomic 
bomb survivors from Hiroshima and Nagasaki (the 
so-called Life Span Study, LSS). The LSS cohort of 
approximately 120,000 survivors (but for the most 
recent analysis, it was restricted to under 100,000) of 
the atomic bombings in Hiroshima and Nagasaki is 
the largest cohort selected for other reasons than 
disease or occupation. It includes both genders and all 
ages at exposure, whole-body exposure (mainly to 
external gamma rays, but a non-negligible ratio of 
neutrons was also present) with a wide range of doses 
(ranging from low doses relevant to diagnostic 
radiology to much higher, even lethal doses) and has 
a long follow-up period (more than 50 years), which 
makes it a very important and unique source of data 
for cancer risk assessment (5-8). The first cancer 
associated with radiation in the LSS population was 
leukaemia and it has had the highest relative risk (ratio 
of the cancer rate in the irradiated group and cancer 
rate among the non-irradiated group) of any other 
cancer.
Statistical modelling cannot begin before cancer 
data assembled during the follow-up period has been 
assigned to dose data. Doses for the LSS population 
were reconstructed using DS86 and DS02 dosimetry 
(9, 10). 
What we know from current data
For medium doses (approx. 0.1-2.5 Gy), LSS data 
suggest an approximately linear relationship between 
dose and solid cancer induction. Leukaemia is a major 
exception for which a linear-quadratic model is the 
accepted standard, because it fits the data significantly 
better than the linear model (7, 11). Above and below 
the medium dose range, the situation is much less 
clear. Although epidemiological data for doses below 
0.1 Gy exist, statistical limitations, i.e. uncertainties, 
are large. The size of an exposed cohort that would be 
required to detect a statistically significant increase in 
cancer risk from doses of interest approximately 
increase as the inverse square of the dose (12). For 
low doses, extremely large epidemiological studies 
would be required to maintain the statistical 
significance of cancer risk results. Therefore, linear 
extrapolation from higher doses, suggested by 
different standard bodies (2, 13-15), is a reasonable 
solution for low doses. 
However, we have to be aware that some known 
effects and phenomena suggest scenarios where linear 
extrapolation could underestimate (e.g., bystander 
effect) or overestimate risk (e.g., adaptive response). 
On the other side of the dose-risk curve, for doses 
above 2.5 Gy, the deviation from linearity and 
reduction of risk due to cell killing and repopulation 
effects are expected. 
The Linear No Threshold model
Several risk models have been developed by 
standard bodies to estimate cancer incidence and 
mortality for low doses: Committee on the Biological 
Effects of lonizing Radiation [BEIR (13)], National 
Council on Radiation Protection and Measurements 
[NCRP (14)], International Commission on 
Radiological Protection [ICRP (2)], and United 
Nations Scientific Committee on the Effects of Atomic 
Radiation [UNSCEAR (15)]. They all have in common 
the assumption of the Linear No Threshold (LNT) 
dose-risk relationship. In other words, risk is directly 
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proportional to the received dose and exists for each 
dose. The uncertainties associated with each model 
are close to, or exceed, variations between the models. 
Using LNT models for a dozen or so different types 
of cancers, as a function of important parameters such 
as gender, age at exposure and time since exposure, 
have been developed. It has also been established and 
used in the field of radiation protection that the average 
risk of developing cancer induced by whole body low 
dose exposures during a lifetime is approximately 
5 % per Sv (2).
Dose and Dose-Rate Effectiveness Factor (DDREF) 
value
Because the LSS population was exposed to a high 
dose rate and risk estimates for low doses had to be 
based on data for higher doses, which following linear 
extrapolation overestimates the risk for low doses, the 
reduction factor called Dose and Dose-Rate 
Effectiveness Factor (DDREF) was introduced. In 
another words, DDREF implies that the radiobiological 
effectiveness of low dose and/or low dose rate 
exposures differs from the effectiveness of high dose 
and/or high dose rate exposures. Values for DDREF 
have been mainly deduced from experiments with 
laboratory animals, radiobiological measurements, 
and statistical methods (Bayesian analysis) on 
epidemiological data. 
In order to be able to rely on the developed models, 
one should be aware of their uncertainty. There are 
two important sources of uncertainty: the very 
procedure to determine the DDREF value and the 
“transport” of cancer risk estimations based on a 
Japanese population to non-Japanese populations, 
particularly those predominantly Caucasian.
BEIR VII and ICRP reduced cancer risk values in 
atomic bomb survivors by a DDREF of 1.5 and 2.0, 
respectively (2, 13). However, a recent review article 
on cancer risk in radiation workers after low dose rate 
and moderate dose exposures reported higher cancer 
risks than BEIR VII and ICRP, implying that their 
DDREF values were overestimated (16). 
To clarify the DDREF, we should use knowledge 
from radiobiology. For doses of up to a few Gy, an 
effect E(D) (e.g., chromosomal aberrations, mutations, 
animal carcinogenesis) induced by an acute dose of 
low-LET (Linear Energy Transfer) radiation (such as 
X and gamma rays) delivered over a few minutes can 
be described by a linear-quadratic function (17):
E(D)=αD+βD2 (I)
Theoretically, the linear and quadratic term can be 
associated with “single-track action” (cell damages 
(e.g. DSBs) are caused by a single track) and “double-
track action” (two or more tracks increase damage of 
the cell), respectively (18). Although, equation (I) is 
most suited for medium doses (0.1-2.5 Gy), it is better 
to use a more simpler linear function (E
Medium
(D)=αMD) 
for fitting data because the corresponding error for 
risk estimates is much smaller than the one caused by 
the uncertainties of the data. 
As already mentioned, equation (I) should be used 
only for leukaemia. For low doses, the probability for 
“double-track action” is negligible, so the quadratic 
term in (I) can be neglected and only the linear term 
is important (E
Low
(D)=αD). E
Medium
(D) and E
Low
(D) are 
different linear functions. If applied for low doses, 
E
Medium
(D) overestimates the risk and therefore 
reduction factor DDREF is used. 
The second important source of uncertainty is the 
“transport” of data and the conclusions that arise from 
it from the studied Japanese population to other 
populations that may have different genetic and life-
style characteristics leading to different baseline risks. 
Basic terms used for risk estimate
The most recent stat ist ical  analyses of 
epidemiological data made for the purpose of cancer 
risk estimates are based on either Excess Absolute 
Risk (EAR) models or Excess Relative Risk (ERR) 
models (2, 13-15). EAR models express excess risk 
as the difference in the total risk and the background 
risk, while ERR models express excess risk relative 
to the background risk. Several measures of lifetime 
risk have been introduced, but our focus is primarily 
on Lifetime Attributable Risk (LAR). LAR is defined 
as the probability that an irradiated person during his 
life could develop cancer induced by radiation. The 
LAR for a person exposed to dose D at age e is 
calculated as follows (13):
 
(II)
where
a = attained age
e = age at exposure
L = latent period i.e. the period during cancer 
incidences caused by radiation are not expected (BEIR 
VII has adopted L = 2 for leukaemia and L = 5 for 
solid cancers)
S(a) = probability of surviving until age a
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S(e) = probability of surviving until age e
M(D, e, a) is a linear combination of EAR(D, e, 
a) and ERR(D, e, a) that depends on how transport 
from one studied population to another is made. 
Two approaches that have been used are 
multiplicative or relative risk transport and additive 
or absolute risk transport (2, 13-15). The first approach 
assumes that the cancer risk induced by radiation 
exposure is proportional to the baseline risk, whereas 
the second presumes the opposite. Results from these 
two approaches can be very different. For example, 
the baseline risk for stomach cancer is much higher 
in Japan than in the United States (13) and there is 
almost an order-of-magnitude difference in the 
estimates of stomach cancer risks based on absolute 
and relative risk transport. For cancer sites other than 
breast, thyroid and lung, BEIR VII (13) recommends 
a weight of 0.7 for the estimates obtained using relative 
risk transport and a weight of 0.3 for the estimates 
obtained using absolute risk transport with the 
weighting done on a logarithmic scale. For example, 
if lifetime attributable risks for the aforementioned 
stomach cancer based on relative and absolute risk 
transport are LARr and LARa, respectively, the final 
result for LAR, combined and adjusted by DDREF is:
  
(III)
Diagrams on Figure 1 illustrate LAR data estimated 
by BEIR VII (13). The BEIR VII table 12D-1 provides 
LAR data for leukaemia and cancer for several 
radiosensitive organs of persons exposed to a single 
dose of 0.1 Gy. Both sexes and eleven discrete ages 
at exposure are covered and LARs for the measured 
organ doses in other studies can be estimated by using 
linear extrapolation and/or interpolation. According 
to these results, the risks are highest for children and 
decrease with age at exposure. For most radiosensitive 
organs, women endure higher risks than men. They 
also have the highest LAR for breast, lung, and thyroid 
cancer, while the highest male LAR is for colon and 
lung cancer.
Other studies
There have been many studies on medically, 
occupationally, and environmentally exposed 
populations whose results have been compared against 
those from the LSS. The results of comparisons are 
always expressed within certain statistical limits.
A few years ago, the largest study of nuclear 
workers found radiation-induced cancer risk consistent 
with the LNT cancer risk models based on LSS data 
(19). Medical studies include patients irradiated for 
the treatment of disease or diagnosis and provide 
valuable information for understanding radiation risk, 
especially for some specific cancers (e.g., thyroid and 
breast) (20). Analysis of childhood cancer risks after 
prenatal X-ray exposures found increased cancer risk 
for the dose of 10 mSv (21). Due to increased interest 
for cancer risk estimate after CT, currently more than 
ten studies concerning risk of cancer after CT for 
different national cohorts are in progress (22). 
Recently, results for the British (23) and Australian 
(24) cohort of children and young adults have been 
published and both assessed the excess cancer risk 
after CT scans. Environmental radiation studies 
comparing medical and occupational data are mostly 
limited and uncertain. The most valuable information 
can be derived from studies after the Chernobyl 
accident (mostly regarding increased risk of radiation-
induced thyroid cancer among children due to 
exposure to radioactive iodine); a recent study (28) 
reports statistically significant increased risk for 
children and adolescents but not for older people.  
The validity of the LNT model and concluding 
remarks
Between 50 and 100 mGy, cancer risk estimates 
based on LSS data lose their conventional statistical 
significance, but for the low dose region they remain 
consistent with the LNT model as well as with some 
nonlinearities (7). Although there is evidence that 
doses of approximately 10 mGy increase the risk of 
certain cancers (21),  according to present 
epidemiological data the lowest dose of photon 
radiation for which reasonably reliable evidence of 
increased cancer risk exists is about 10-50 mGy for 
single and 50-100 mGy for protracted exposure (25). 
There is no doubt that present cancer risk models can 
be used for doses above the mentioned limit, but one 
should always be careful with extrapolation to lower 
doses (especially below 10 mGy). 
Reducing the dose and approaching the level of 
background radiation, things become even more 
unclear and it has to be borne in mind that values for 
estimated risk of radiation-induced cancer will be very 
small and comparable with variations in baseline risk 
(e.g., smoking). It would be impossible to make an 
adequate epidemiological LNT test for doses below 
approx.10 mGy and controversies (26, 27) will always 
exist.
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However, evidence for cancer risk after low dose 
exposure exists and that risk can be predicted by 
current LNT models. The LNT model is still the most 
robust and most frequently used model for making 
cost-benefit decisions in medical exposures, but 
improvements to existing models as well as new 
findings for the low dose region are eagerly awaited. 
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Sažetak
Procjena rizika za nastanak karcinoma zbog izloženosti malim dozama ionizirajućeg zračenja
Unatoč velikoj važnosti i koristi ionizirajućeg zračenja u dijagnosticiranju i liječenju mnogih bolesti, 
treba imati na umu da se ozračivanjem zdravog tkiva može povećati rizik od karcinoma. Stoga je 
vrlo važno znati kakve rizike možemo očekivati ovisno o primljenoj dozi zračenja. Za razliku od 
područja srednjih i velikih doza za koje su štetni učinci dobro poznati, područje malih doza (ispod 
0,1 Gy) puno je nejasnoća, a procjena rizika vrlo je važna. U ovom radu prikazane su osnovne 
pretpostavke i koraci u procjeni rizika od karcinoma uzrokovanih zračenjem u području malih doza.
KLJUČNE RIJEČI: faktor DDREF; epidemiologija; LSS; model LNT; radijacijski rizik; zračenje niskog 
LET-a
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